1. One year of omega 3 polyunsaturated fatty acid supplementation does not reduce circulating prothrombotic microvesicles in elderly subjects after suffering a myocardial infarction.
- Author
-
Chiva-Blanch G, Bratseth V, Laake K, Arnesen H, Solheim S, Schmidt EB, Badimon L, and Seljeflot I
- Subjects
- Aged, Biomarkers blood, Cohort Studies, Female, Follow-Up Studies, Humans, Male, Norway, Thrombosis drug therapy, Cell-Derived Microparticles drug effects, Cell-Derived Microparticles metabolism, Dietary Supplements, Fatty Acids, Omega-3 administration & dosage, Fatty Acids, Omega-3 therapeutic use, Myocardial Infarction drug therapy
- Abstract
Background & Aims: Circulating microvesicles (cMV) are both effectors and biomarkers of cardiovascular disease (CVD), and the effects of omega 3 polyunsaturated fatty acids (n3 PUFA) in MV shedding are not yet well known. Therefore, we aimed to investigate the effects of long-term n3 PUFA supplementation on cMV release from cells of the vascular compartment in elderly subjects at very high risk of CVD., Methods: We included 156 elderly patients 2-8 weeks after suffering an acute myocardial infarction from the OMEMI cohort. Subjects were randomly allocated to receive 930 mg EPA + 660 mg DHA (n3 PUFA intervention) or corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid) used as placebo daily for two years. At inclusion and after one-year follow-up, prothrombotic [annexin V (AV)
+ ] cMV derived from blood and vascular cells were phenotyped by flow cytometry., Results: No differences were observed in the levels of cMV between the randomized groups at inclusion in the study. After one-year follow-up, total AV+ , platelet-derived CD61+ /AV+ , and endothelial-derived CD31+ /AV+ and CD31+ /CD42b- /AV+ cMV increased significantly in both groups. In the n3 PUFA supplemented group, platelet-derived CD62P+ /AV+ , CD42b+ /AV+ and CD31+ /CD42b+ /AV+ ; leukocyte-derived CD62L+ /AV+ , CD45+ /AV+ , and CD11b+ /AV+ , as well as endothelial derived CD146+ /AV+ , CD62E+ /AV+ , and CD309+ /AV+ cMV also increased significantly. No significant differences were however, observed in the changes of cMV levels between groups., Conclusion: In elderly Norwegians who have suffered a recent acute myocardial infarction and treated as per guidelines, long-term supplementation with 1.8 g/day n3 PUFA does not modulate prothrombotic MV release from blood and vascular cells., Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01841944., Competing Interests: Conflict of Interest The authors declare no conflicts of interest., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF